RDAA-positive NSCLC cells exhibited higher sensitivity to U.S. Food and Drug Administration (FDA)-approved ALK inhibitors compared to cells expressing RNase1 or ALK alone. This evidence concerns the gene ALK and non-small cell lung carcinoma.